Company / Cash & Equivalents
MEDIFAST INC Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$89.3M
FY2025
5-year range
$77.0M / $163.7M
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $164M in FY2020 to $89M in FY2025.
Based on SEC 10-K filings.
$89M in FY2025 with a 10-year CAGR of +9.4%.
Declined from $94M to $89M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -11.4%
- 10-Year CAGR
- +9.4%
Key checks
Key Insights
- MEDIFAST INC's cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -11.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 1.8% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 4.08 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.3M | -1.8% |
| FY2024 | $90.9M | -3.7% |
| FY2023 | $94.4M | -42.3% |
| FY2020 | $163.7M | +112.7% |
| FY2019 | $77.0M | +2.5% |
| FY2018 | $75.1M | +78.6% |
| FY2017 | $42.0M | +71.9% |
| FY2016 | $24.5M | -32.8% |
| FY2015 | $36.4M | -8.9% |
| FY2014 | $39.9M | +180.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026